Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/221349
Title: | Real-world experience of Teduglutide use in adults with short bowel syndrome: A seven-year international multicenter survey |
Author: | Joly, Francisca Jezerski, Denise Pape, Ulrich-Frank Crivelli, Adriana Huetterer, Elisabeth Bergoin, Charlotte Sasdelli, Anna Simona Aimasso, Umberto Schneider, Stéphane M. Poullenot, Florian Seguy, David Chapman, Brooke Sobocki, Jacek Regano, Nunzia Lamprecht, Georg Layec, Sabrina Santarpia, Lidia Kozjek, Nada Rotovnik Gallitelli, Livia López Urdiales, Rafael Fehr, Rebecca Itzhaki, Moran Hellerman Maíz Jiménez, María Carey, Sharon Taus, Marina Francini Pesenti, Francesco Rasmussen, Henrik H. Vanuytsel, Tim Cuerda Compes, Cristina Thibault, Ronan Chen, Mona Osland, Emma Krznaric, Zeljko Martins da Rocha, Mariana Hollanda Martinuzzi, Andrés L. N. Bezmarevic, Mihailo Bueno Diez, Marta Livovsky, Dan M. Serrano Aguayo, Pilar Orlandoni, Paolo Burgos Peláez, Rosa Campos Martín, Cristina Ellegard, Lars Lezo, Antonella Ramos Boluda, Esther Gandullia, Paolo Bluethner, Elizabeth Zarpellon, Martina Lal, Simon Pironi, Loris |
Keywords: | Malalties de l'aparell digestiu Terapèutica Digestive system diseases Therapeutics |
Issue Date: | 17-Feb-2025 |
Publisher: | Elsevier BV |
Abstract: | Background and aim: Teduglutide is a glucagon-like peptide-2 analogue used to promote intestinal rehabilitation and decrease the dependence from intravenous supplementation (IVS) in patients with short bowel syndrome and intestinal failure (SBS-IF). The aim of this study was to gain a better understanding of international real-world Teduglutide use since its launch. Methods: Data from an international multicenter database for chronic IF were analysed. All the adult patients with SBS-IF included by centers that treated at least one patient with Teduglutide during the study period (2015-2022) were investigated. The baseline characteristics and the outcome of patients treated with Teduglutide (n.269) were compared to those of patients not receiving the drug (Controls, n.3081). The center experience was categorized based on the number of patients treated with Teduglutide: <10 or >= 10. Results: Teduglutide cohort exhibited higher male prevalence, younger age, longer duration of HPN, higher percentage of SBS with jejunocolonic anastomosis, lower IVS volume, improved oral intake, and higher percentage of patients weaned from IVS. Controls showed higher percentages of patients deceased or lost to follow up. Centers with >= 10 patients treated with Teduglutide showed higher weaning rates and lower mortality rates. Conclusions: This is the largest analysis of Teduglutide's real-world setting in SBS-IF. Clinicians preferentially selected for treatment patients with better prognostic indicators. Outcomes were significantly better in centers with higher Teduglutide treatment volumes, emphasizing the need for specialized referral centers to optimize care for SBS-IF patients. (c) 2025 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights are reserved, including those for text and data mining, AI training, and similar technologies. |
Note: | Reproducció del document publicat a: https://doi.org/10.1016/j.clnu.2025.01.026 |
It is part of: | Clinical Nutrition, 2025, vol. 47, p. 54-67 |
URI: | https://hdl.handle.net/2445/221349 |
Related resource: | https://doi.org/10.1016/j.clnu.2025.01.026 |
ISSN: | 0261-5614 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
1-s2.0-S0261561425000275-main.pdf | 480.32 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License